FUSION ANTIBODIES PLC

Report Publication Announcement • Sep 19, 2025

National Storage Mechanism | Additional information

RNS Number : 1048A

Fusion Antibodies PLC

19 September 2025

Fusion Antibodies plc

("Fusion" or the "Company")

Posting of Annual Report & Notice of AGM

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Annual Report and Accounts for the year ended 31 March 2025 and the Notice of the Company's Annual General Meeting ("AGM") is being posted to shareholders today.

The Notice of AGM and accompanying form of proxy will shortly be available to download from the Company website here:  https://www.fusionantibodies-ir.com/ .

The AGM will be held on Thursday, 16 October 2025 at 11.00 a.m. at the offices of Fusion Antibodies plc, 1 Springbank Road, Springbank Industrial Estate, Belfast BT17 0QL.

Enquiries: 

Investor questions on this announcement
We encourage all investors to share questions on this announcement via our investor hub		Investor hub
Fusion Antibodies plc		www.fusionantibodies.com
Adrian Kinkaid, Chief Executive Officer Stephen Smyth, Chief Financial Officer		Via Walbrook PR
Allenby Capital Limited		Tel: +44 (0) 20 3328 5656
James Reeve/Vivek Bhardwaj (Corporate Finance) Tony Quirke/Joscelin Pinnington (Sales and Corporate Broking)
Shard Capital Partners LLP
Damon Heath (Joint Broker)		Tel: +44 (0) 207 186 9952
Walbrook PR	Tel: +44 (0)20 7933 8780 or [email protected]
Anna Dunphy		Mob: +44 (0)7876 741 001

About Fusion Antibodies plc

Fusion is a Belfast based contract research organisation ("CRO") providing a range of antibody engineering services for the development of antibodies for both therapeutic drug and diagnostic applications.

The Company's ordinary shares were admitted to trading on AIM on 18 December 2017. Fusion provides a broad range of services in antibody generation, development, production, characterisation and optimisation. These services include antigen expression, antibody production, purification and sequencing, antibody humanisation using Fusion's proprietary CDRx TM platform and the production of antibody generating stable cell lines to provide material for use in clinical trials. Since 2012, the Company has successfully sequenced and expressed over 250 antibodies and successfully completed over 200 humanisation projects and has an international, blue-chip client base, which has included eight of the top 10 global pharmaceutical companies by revenue.

The Company was established in 2001 as a spin out from Queen's University Belfast. The Company's mission is to enable pharmaceutical and diagnostic companies to develop innovative products in a timely and cost-effective manner for the benefit of the global healthcare industry. Fusion Antibodies provides a broad range of services in antibody generation, development, production, characterisation and optimisation.

Fusion Antibodies growth strategy is based on combining the latest technological advances with cutting edge science to deliver new platforms that will enable Pharma and Biotech companies get to the clinic faster, with the optimal drug candidate and ultimately speed up the drug development process. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOAKZGMLMLVGKZM